XL 281

Drug Profile

XL 281

Alternative Names: BMS-908662; XL-281

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Exelixis
  • Developer Bristol-Myers Squibb; Exelixis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Raf kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Colorectal cancer; Malignant melanoma

Most Recent Events

  • 11 Jun 2013 Bristol-Myers Squibb completes a phase I trial in Malignant melanoma in USA (NCT01245556)
  • 31 Oct 2011 XL 281 is no longer licensed to Bristol-Myers Squibb
  • 29 Sep 2011 Bristol-Myers Squibb completes a phase I/II trial in Colorectal cancer (metastatic disease, in combination with cetuximab) in US and Canada (NCT01086267)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top